Triheptanoin for the treatment of brain energy deficit: A 14-year experience.

about

Individualizing Treatment Approaches for Epileptic Patients with Glucose Transporter Type1 (GLUT-1) Deficiency.

P2860

Q47882020-57F64627-0089-41E9-A723-8C5C350C773E

P2860

Triheptanoin for the treatment of brain energy deficit: A 14-year experience.

Item

http://www.wikidata.org/entity/Q39422277

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Triheptanoin for the treatment of brain energy deficit: A 14-year experience.

@en

Triheptanoin for the treatment of brain energy deficit: A 14-year experience.

@nl

type

Item

label

Triheptanoin for the treatment of brain energy deficit: A 14-year experience.

@en

Triheptanoin for the treatment of brain energy deficit: A 14-year experience.

@nl

prefLabel

Triheptanoin for the treatment of brain energy deficit: A 14-year experience.

@en

Triheptanoin for the treatment of brain energy deficit: A 14-year experience.

@nl

P1476

Triheptanoin for the treatment of brain energy deficit: A 14-year experience.

@en

P2093

Fanny Mochel

http://www.w3.org/2001/XMLSchema#string

P2860

Anaplerotic triheptanoin diet enhances mitochondrial substrate use to remodel the metabolome and improve lifespan, motor function, and sociability in MeCP2-null mice

Heptanoate as a neural fuel: energetic and neurotransmitter precursors in normal and glucose transporter I-deficient (G1D) brain

Early alterations of brain cellular energy homeostasis in Huntington disease models

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay

Triheptanoin improves brain energy metabolism in patients with Huntington disease

Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice

Metabolic control through the PGC-1 family of transcription coactivators

Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease

Glut1 deficiency (G1D): epilepsy and metabolic dysfunction in a mouse model of the most common human phenotype.

P304

2236-2243

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JNR.24111

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Fanny Mochel

P577

2017-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28688166

http://www.w3.org/2001/XMLSchema#string

Triheptanoin for the treatment of brain energy deficit: A 14-year experience.

about

P2860

P2860

Triheptanoin for the treatment of brain energy deficit: A 14-year experience.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698